Literature DB >> 21813176

ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia.

H Elizabeth Broome1, Laura Z Rassenti, Huan-You Wang, Lilly M Meyer, Thomas J Kipps.   

Abstract

ROR1 is a receptor tyrosine kinase expressed during embryogenesis, on chronic lymphocytic leukemia (CLL) and in other malignancies. Hematogones (non-neoplastic B-lymphocyte precursors) express surface ROR1 at an intermediate stage of maturation that lacks CD34 or TdT. The neoplastic counterpart to hematogones is precursor-B acute lymphoblastic leukemia (B-ALL), but less than 10% of B-ALL express surface ROR1, and these ROR1+ B-ALL cases have an unusually high frequency of lacking CD34 and/or having t(1;19), a chromosomal translocation that defines a specific subtype of B-ALL.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813176      PMCID: PMC3163753          DOI: 10.1016/j.leukres.2011.06.021

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  14 in total

1.  Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.

Authors:  P Lúcio; A Parreira; M W van den Beemd; E G van Lochem; E R van Wering; E Baars; A Porwit-MacDonald; E Bjorklund; G Gaipa; A Biondi; A Orfao; G Janossy; J J van Dongen; J F San Miguel
Journal:  Leukemia       Date:  1999-03       Impact factor: 11.528

2.  Expansion of B cell precursors after unrelated cord blood transplantation for an adult patient.

Authors:  D Mattei; R Bassan; N Mordini; D Rapezzi; A Rambaldi; G Strola; C Peretti; F Del Grosso; A M Ferraris; C Castellino; A Gallamini
Journal:  Bone Marrow Transplant       Date:  2007-05-28       Impact factor: 5.483

3.  Tolerance checkpoints in B-cell development: Johnny B good.

Authors:  Roxane Tussiwand; Nabil Bosco; Rhodri Ceredig; Antonius G Rolink
Journal:  Eur J Immunol       Date:  2009-09       Impact factor: 5.532

4.  The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

Authors:  Michael Hudecek; Thomas M Schmitt; Sivasubramanian Baskar; Maria Teresa Lupo-Stanghellini; Tetsuya Nishida; Tori N Yamamoto; Marie Bleakley; Cameron J Turtle; Wen-Chung Chang; Harvey A Greisman; Brent Wood; David G Maloney; Michael C Jensen; Christoph Rader; Stanley R Riddell
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

5.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.

Authors:  Tetsuya Fukuda; Liguang Chen; Tomoyuki Endo; Li Tang; Desheng Lu; Januario E Castro; George F Widhopf; Laura Z Rassenti; Mark J Cantwell; Charles E Prussak; Dennis A Carson; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

6.  Contrasting responses of lymphoid progenitors to canonical and noncanonical Wnt signals.

Authors:  Sachin Malhotra; Yoshihiro Baba; Karla P Garrett; Frank J T Staal; Rachel Gerstein; Paul W Kincade
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

7.  Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study.

Authors:  M J Borowitz; S P Hunger; A J Carroll; J J Shuster; D J Pullen; C P Steuber; M L Cleary
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

8.  Hematogones in the bone marrow of adults. Immunophenotypic features, clinical settings, and differential diagnosis.

Authors:  R E Davis; T A Longacre; P J Cornbleet
Journal:  Am J Clin Pathol       Date:  1994-08       Impact factor: 2.493

9.  RNAi screen for rapid therapeutic target identification in leukemia patients.

Authors:  Jeffrey W Tyner; Michael W Deininger; Marc M Loriaux; Bill H Chang; Jason R Gotlib; Stephanie G Willis; Heidi Erickson; Tibor Kovacsovics; Thomas O'Hare; Michael C Heinrich; Brian J Druker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

10.  Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.

Authors:  Sivasubramanian Baskar; Ka Yin Kwong; Thomas Hofer; Jessica M Levy; Michael G Kennedy; Elinor Lee; Louis M Staudt; Wyndham H Wilson; Adrian Wiestner; Christoph Rader
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

View more
  41 in total

Review 1.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

2.  Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Authors:  Michael Y Choi; George F Widhopf; Emanuela M Ghia; Reilly L Kidwell; Md Kamrul Hasan; Jian Yu; Laura Z Rassenti; Liguang Chen; Yun Chen; Emily Pittman; Minya Pu; Karen Messer; Charles E Prussak; Januario E Castro; Catriona Jamieson; Thomas J Kipps
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

3.  ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.

Authors:  Rajeswaran Mani; Chi-Ling Chiang; Frank W Frissora; Ribai Yan; Xiaokui Mo; Sivasubramanian Baskar; Christoph Rader; Rebecca Klisovic; Mitch A Phelps; Ching-Shih Chen; Robert J Lee; John C Byrd; Robert Baiocchi; L James Lee; Natarajan Muthusamy
Journal:  Exp Hematol       Date:  2015-04-29       Impact factor: 3.084

Review 4.  Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.

Authors:  Michael Y Choi; George F Widhopf; Christina C N Wu; Bing Cui; Fitzgerald Lao; Anil Sadarangani; Joy Cavagnaro; Charles Prussak; Dennis A Carson; Catriona Jamieson; Thomas J Kipps
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

5.  Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.

Authors:  Jian Yu; Liguang Chen; Bing Cui; George F Widhopf; Zhouxin Shen; Rongrong Wu; Ling Zhang; Suping Zhang; Steven P Briggs; Thomas J Kipps
Journal:  J Clin Invest       Date:  2016-02       Impact factor: 14.808

6.  MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Veronica Balatti; Emanuela M Ghia; Alexey Palamarchuk; Luisa Tomasello; Paolo Fadda; Yuri Pekarsky; George F Widhopf; Thomas J Kipps; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

7.  Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting β-catenin and AKT signaling but frequently methylated in common carcinomas.

Authors:  Lili Li; Jianming Ying; Xin Tong; Lan Zhong; Xianwei Su; Tingxiu Xiang; Xingsheng Shu; Rong Rong; Lei Xiong; Hongyu Li; Anthony T C Chan; Richard F Ambinder; Yajun Guo; Qian Tao
Journal:  Cell Mol Life Sci       Date:  2013-10-25       Impact factor: 9.261

Review 8.  Noncoding RNA genes in cancer pathogenesis.

Authors:  Yuri Pekarsky; Carlo M Croce
Journal:  Adv Biol Regul       Date:  2018-12-13

9.  Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.

Authors:  Vincent T Bicocca; Bill H Chang; Behzad Kharabi Masouleh; Markus Muschen; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal:  Cancer Cell       Date:  2012-11-13       Impact factor: 31.743

Review 10.  The pathogenesis of chronic lymphocytic leukemia.

Authors:  Suping Zhang; Thomas J Kipps
Journal:  Annu Rev Pathol       Date:  2013-08-26       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.